BMS-470539

Experimental drug

{{Infobox drug | IUPAC_name = (2S)-2-[[6-[[2-(2,3-dihydro-1H-inden-2-yl)ethyl]amino]-9H-purin-9-yl]methyl]butanedioic acid | image = | width = | alt = | image2 = | width2 = | alt2 = | tradename = | Drugs.com = | MedlinePlus = | licence_EU = | DailyMedID = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | routes_of_administration = | ATC_prefix = | ATC_suffix = | legal_AU = | legal_BR = | legal_CA = | legal_DE = | legal_IN = | legal_NZ = | legal_UK = | legal_US = | legal_status = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 330786-25-9 | PubChem = 9935741 | IUPHAR_ligand = | DrugBank = | ChemSpiderID = 8110739 | UNII = | KEGG = | ChEBI = | ChEMBL = | PDB_ligand = | synonyms = | C=20 | H=24 | N=6 | O=4 | smiles = | StdInChI = | StdInChIKey = }}

BMS-470539 is an experimental drug developed by Bristol-Myers Squibb. It is primarily studied for its potential effects on the melanocortin receptor system, particularly the melanocortin 1 receptor (MC1R).

Mechanism of Action

BMS-470539 functions as a selective agonist for the melanocortin 1 receptor (MC1R). The activation of MC1R is associated with various physiological effects, including anti-inflammatory responses and pigmentation changes. The drug's ability to selectively target MC1R makes it a potential candidate for treating conditions related to inflammation and pigmentation disorders.

Potential Applications

Research on BMS-470539 has indicated its potential in treating a variety of conditions:

• Inflammatory diseases: Due to its anti-inflammatory properties, BMS-470539 may be useful in treating diseases characterized by chronic inflammation.
• Pigmentation disorders: By targeting MC1R, BMS-470539 could be used to manage conditions such as vitiligo and other pigmentation abnormalities.

Development and Research

BMS-470539 is still in the experimental stages, and its safety and efficacy have not yet been fully established. Ongoing research aims to better understand its pharmacokinetics, optimal dosing, and potential side effects.

See Also

• Melanocortin receptor
• MC1R
• Inflammatory diseases
• Pigmentation disorders